title: Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
abstract: Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.
authors: Division of Nephrology, Keck School of Medicine, University of Southern California, 2020 Zonal Avenue, Los Angeles, CA 90033, USA. campese@usc.edu
authors: Vito M
authors: VM
authors: Campese
authors: Elaine
authors: E
authors: Ku
authors: Roberto
authors: R
authors: Bigazzi
authors: Stefano
authors: S
authors: Bianchi
mesh_terms: D019317:Evidence-Based Medicine; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000503:physiopathology; D018579:Patient Selection; D011507:Proteinuria / Q000188:drug therapy / Q000503:physiopathology; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors